Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitisopen access
- Authors
- Na, Soo-Young; Choi, Chang Hwan; Song, Eun Mi; Bang, Ki Bae; Park, Sang Hyoung; Kim, Eun Soo; Park, Jae Jun; Keum, Bora; Lee, Chang Kyun; Lee, Bo-In; Ryoo, Seung-Bum; Koh, Seong-Joon; Choi, Miyoung; Kim, Joo Sung; IBD Research Group of Korean Association for the Study of Intestinal Diseases
- Issue Date
- May-2022
- Publisher
- 대한장연구학회
- Keywords
- Colitis; ulcerative; Inflammatory bowel disease; Management; Guideline
- Citation
- Intestinal research, v.21, no.1, pp 61 - 87
- Pages
- 27
- Indexed
- SCOPUS
ESCI
KCI
- Journal Title
- Intestinal research
- Volume
- 21
- Number
- 1
- Start Page
- 61
- End Page
- 87
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/61119
- DOI
- 10.5217/ir.2022.00007
- ISSN
- 1598-9100
2288-1956
- Abstract
- Ulcerative colitis (UC), a relapsing-remitting chronic inflammatory bowel disease (IBD), has a variable natural course but potentially severe disease course. Since the development of anti-tumor necrosis factor (TNF) agents has changed the natural disease course of moderate-to-severe UC, therapeutic options for patients who failed conventional treatments are expanding rapidly. IBD clinical trials have demonstrated the potential efficacy and safety of novel biologics such as anti-integrin alpha 4 beta 7 and antiinterleukin-12/23 monoclonal antibodies and small molecules such as a Janus kinase inhibitor. Anti-TNF biosimilars also have been approved and are widely used in IBD patients. Wise drug choices should be made considering evidence-based efficacy and safety. However, the best position of these drugs remains several questions, with limited data from direct comparative trials. In addition, there are still concerns to be elucidated on the effect of therapeutic drug monitoring and combination therapy with immunomodulators. The appropriate treatment regimens in acute severe UC and the risk of perioperative use of biologics are unclear. As novel biologics and small molecules have been approved in Korea, we present the Korean guidelines for medical management of adult outpatients with moderate-to-severe UC and adult hospitalized patients with acute severe UC, focusing on biologics and small molecules.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.